



Genetic Risk, Lifestyle, and Age-Related Macular Degeneration in Europe

The EYE-RISK Consortium

Johanna M. Colijn, MD, MSc,^{1,2} Magda Meester-Smoor, PhD,^{1,2} Timo Verzijden, MSc,^{1,2} Anita de Breuk, MD,³ Rufino Silva, MD, PhD,^{4,5,6} Benedicte M.J. Merle, PhD,⁷ Audrey Cougnard-Grégoire, PhD,⁷ Carel B. Hoyng, MD, PhD,³ Sascha Fauser, MD, PhD,^{8,9} Anthonius Coolen, PhD,^{10,11} Catherine Creuzot-Garcher, MD, PhD,¹² Hans-Werner Hense, MD, PhD,¹³ Marius Ueffing, PhD,¹⁴ Cecile Delcourt, PhD,⁷ Anneke I. den Hollander, PhD,³ Caroline C.W. Klaver, PhD,^{1,2,3,15} for the EYE-RISK Consortium*

Purpose: Age-related macular degeneration (AMD) is a common multifactorial disease in the elderly with a prominent genetic basis. Many risk variants have been identified, but the interpretation remains challenging. We investigated the genetic distribution of AMD-associated risk variants in a large European consortium, calculated attributable and pathway-specific genetic risks, and assessed the influence of lifestyle on genetic outcomes.

Design: Pooled analysis of cross-sectional data from the European Eye Epidemiology Consortium.

Participants: Seventeen thousand one hundred seventy-four individuals 45 years of age or older participating in 6 population-based cohort studies, 2 clinic-based studies, and 1 case-control study.

Methods: Age-related macular degeneration was diagnosed and graded based on fundus photographs. Data on genetics, lifestyle, and diet were harmonized. Minor allele frequencies and population-attributable fraction (PAF) were calculated. A total genetic risk score (GRS) and pathway-specific risk scores (complement, lipid, extra-cellular matrix, other) were constructed based on the dosage of SNPs and conditional β values; a lifestyle score was constructed based on smoking and diet.

Main Outcome Measures: Intermediate and late AMD.

Results: The risk variants with the largest difference between late AMD patients and control participants and the highest PAFs were located in *ARMS2* (rs3750846) and *CHF* (rs570618 and rs10922109). Combining all genetic variants, the total genetic risk score ranged from -3.50 to 4.63 and increased with AMD severity. Of the late AMD patients, 1581 of 1777 (89%) showed a positive total GRS. The complement pathway and *ARMS2* were by far the most prominent genetic pathways contributing to late AMD (positive GRS, 90% of patients with late disease), but risk in 3 pathways was most frequent (35% of patients with late disease). Lifestyle was a strong determinant of the outcome in each genetic risk category; unfavorable lifestyle increased the risk of late AMD at least 2-fold.

Conclusions: Genetic risk variants contribute to late AMD in most patients. However, lifestyle factors have a strong influence on the outcome of genetic risk and should be a strong focus in patient management. Genetic risks in *ARMS2* and the complement pathway are present in most late AMD patients but are mostly combined with risks in other pathways. *Ophthalmology* 2021;128:1039-1049 © 2020 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Supplemental material available at www.aajournal.org.

Age-related macular degeneration (AMD) is a progressive degenerative disease of the retina and the most important cause of blindness in the Western world. Projections show that in up to 4.8 million Europeans and up to 18.6 million persons worldwide, a blinding stage of AMD will develop by 2040.^{1,2} Age-related macular degeneration is classified into 2 end stages: a more common wet form characterized by choroidal neovascularization (CNV) and a dry form

characterized by geographic atrophy (GA) of the retinal pigment epithelium.³ Only the wet form can be treated with anti-vascular endothelial growth factor agents, but visual decline remains inevitable in the long term.⁴

Age-related macular degeneration is a complex genetic disease that is influenced strongly by a combination of environmental and genetic factors. In particular, smoking and diet are known to increase the risk of AMD

considerably. The genetic cause is well established: 52 common, known AMD-associated variants and more than 100 rare variants have been reported.^{5,6} These variants explain most of the disease causes and helped to pinpoint several pathogenic pathways. Of these, the complement cascade seemed to be most important, but the first attempts to target this pathway in intervention trials have achieved limited success.^{7,8} This raises the question of whether disease pathways are specific to groups of individuals. If this is the case, intervention trials may be more successful by stratifying patients based on the major disease pathway driving their disease.

In this study, we aimed to investigate the contribution of genetic variants to AMD risk in Europe using data from the large European Eye Epidemiology (E3) Consortium. We aimed to determine the contribution of each disease pathway in AMD and investigated whether lifestyle changes can reduce the risk of late AMD, in particular in individuals with a high genetic risk of AMD.

Methods

Study Population

The E3 Consortium is a European collaboration of studies with epidemiologic data on common eye disorders; a detailed description on the consortium can be found elsewhere.⁹ All data on AMD were harmonized and collected in the EYE-RISK database (version 6.0). Nine studies from France, Germany, The Netherlands, and Portugal produced data on AMD genotype and phenotype available for analysis and were enrolled as a pooled dataset in the current study. The cohort descriptions of the included studies are listed in the Appendix (available at www.aaojournal.org). The Combined Ophthalmic Research Rotterdam Biobank, Muenster Aging and Retina Study (MARS), and the European Genetic Database were clinic-based studies, and the remaining studies were population based (the Rotterdam Study I, II, and III; Alienor-3C [Antioxidants, Essential Lipids, Nutrition and Ocular Diseases—3 cities]; Montrachet-3C [Maculopathy Optic Nerve nuTRition neurovascular and HEarT diseases—3 cities]; and the Coimbra Eye Study). Persons 45 years of age and older were included in the analyses; various analyses included only control participants 75 years of age or older. The recruitment and research protocols were reviewed and approved by the local institutional review boards. All studies were performed in accordance with the tenets of the Declaration of Helsinki for research involving human subjects and good epidemiologic practice guidelines, and written informed consent was obtained from all participants.

Clinical Examination

The phenotype of AMD was determined on fundus photographs centered on the macula; individuals received the diagnosis of the worst eye. Age-related macular degeneration features were graded locally by clinicians or experienced graders; classifications were grouped into 3 severity groups. Control participants did not display AMD, aside from only small drusen or only pigment irregularities; persons with early or intermediate AMD showed soft indistinct (large) drusen, reticular drusen, or both, with or without pigmentary irregularities, and further were considered to have intermediate AMD; persons with late AMD had GA or CNV; and persons with both end stages were diagnosed as having CNV. Lifestyle factors including smoking and dietary habits were assessed by questionnaire.

Genetic Analyses and Risk Scores

Age-related macular degeneration genetic risk variants were ascertained from the EYE-RISK and E3 database.^{5,9} Studies used various platforms to determine the 52 known risk variants, such as whole-exome sequencing, exome chip (Illumina HumanExome BeadChip), genomic single-nucleotide polymorphism (SNP) arrays (Illumina 550K [duo] chip or Illumina 610 quad), or TaqMan assays, and a custom-made AMD genotyping platform using single-molecule molecular inversion probes with next-generation sequencing; for the EYE-RISK genotype assay,¹⁰ see cohort descriptions. If variants had been determined by multiple methods that included direct genotyping, we used data from the latter method. When no direct genotyping was available, genotypes were dosages derived from Haplotype Reference Consortium imputation or 1000G. Three (rs71507014, rs67538026, and rs142450006) of the 52 known AMD risk variants could not be included in our analysis because genotypes were not available for multiple cohorts.

Genetic risk scores (GRS) were calculated for the 17 174 individuals for whom the 5 major risk variants (*CFH* rs10922109, *CFH* rs570618, *C2* rs429608, *C3* rs2230199, and *ARMS2* rs3750846) were available. Complete genotype data on minor risk alleles were available in 62.3% persons; 85.1% individuals had 47 of 49 variants. Genetic risk scores were calculated by multiplying the conditional β value of the AMD risk variant⁷ with the allele dosage. Subsequently, all calculations were summed. Pathway-specific GRSs were constructed in the same manner. For the complement GRSs, we included all risk variants in the *CFH*, *CFI*, *C9*, *C2*, *TMEM97/VTN*, and *C3* genes. For the lipid GRSs, variants in *ABCA1*, *LIPC*, *CETP*, and *APOE* were included. For the extracellular matrix (ECM) GRS, variants in *COL4A3*, *ADAMTS9-AS2*, *COL8A1*, *VEGFA*, and *SYN3/TIMP3* were included. The remaining variants were included in “other” GRSs. The function of *ARMS2* mostly was considered unsettled. However, because recent evidence suggests a role in the complement pathway,¹¹ we analyzed this gene as a stand-alone pathway GRS as well as part of the complement pathway GRS.

Lifestyle Score

Four well-established AMD lifestyle determinants (smoking status and servings of vegetables, fruit, and fish per day) were assessed by questionnaire. Smoking status was categorized as no, former, or current smoker. Dietary intakes were analyzed in medium servings per day with a maximum of 1, that is, 120 g of vegetables per day, 120 g of fruit per day, and 100 g of fish per day. β coefficients for associations with late AMD were calculated by multivariate logistic regression, were multiplied by determinant values, and were summed to create a lifestyle risk score. Lifestyle risk scores were stratified into tertiles as an unfavorable, intermediate, or favorable lifestyle.

Statistical Analysis

The population-attributable fraction (PAF) was calculated for each variant using the formula of Miettinen¹²: $PAF = Pc \times ((OR - 1) / OR)$, where OR is the odds ratio and Pc is the proportion of exposed patients among the patients. The pooled dataset formed the basis for all analysis. We calculated the discriminative accuracy between late AMD patients and control participants for our model of genetic factors using Saddle Point Signature software version 2.8.3 (Saddle Point Science, Ltd., Worcester Park, United Kingdom) in a batch multivariate regression analysis. Results were cross-validated by the leave-one-out principle. Prediction performance at each iteration was quantified by counting errors of persons assigned to the wrong category (control

participants or patients). The dataset was fully balanced between control participants and patients; the regression equations corresponded to a pseudo-dataset, in which the outcome classes were equal in size, but the other statistical features were identical to the true dataset. Missing values were not set to 0 but rather, imputed to the mean. Covariates were selected based on error expectation minimization.

Where appropriate, comparisons were made with the Pearson chi-square test, Jonckheere-Terpstra test for ordered alternatives, or independent-sample *t* test. Interaction of genetic and lifestyle risk was assessed by a univariate analysis of variance. Graphical outputs were constructed with GraphPad Prism 5 version 7.00 for Windows software (GraphPad Software, La Jolla, CA). Histograms and a receiver operator characteristic curve were constructed with SPSS Statistics for Windows version 25.0 (IBM Corp).

Results

We identified a total of 17 174 individuals 45 years of age or older with data on genetics and AMD: 13 324 persons without AMD, 2073 persons with intermediate AMD, and 1777 persons with late AMD. Of the persons with late AMD, 309 demonstrated GA, and 1468 demonstrated CNV. Age ranged from 45 to 101 years old, with a mean of 68.7 years (standard deviation [SD], 10.4), the proportion of women was 58.5%, the proportion of current smoker was 16.8% (*n* = 2888), and the proportion of former smokers was 39.5% (*n* = 6786). For risk calculations, we aimed to ensure a true phenotype of no AMD and therefore included only control participants 75 years of age or older (*n* = 3167) in these analyses. The proportion of women in this subset (control participants 75 years of age or older and patients with intermediate or late AMD) was 61.3%, the proportion of current smokers was 9% (*n* = 630), and the proportion of former smokers was 36.2% (*n* = 2541).

Single Variants

First, we focused on frequency distributions of the 49 single-risk variants in the 3 phenotype groups and ranked variants according to frequency differences between late and no AMD (Fig 1A). Single-nucleotide polymorphisms from the complement pathway and *ARMS2* showed the largest difference in frequency between patients and control participants (rs10922109, rs61818925, and rs570618 [CFH]; rs429608 [C2]; rs2230199 [C3]; and rs3750846 [ARMS2]). Among the first 10 variants, 5 variants showed a lower frequency among patients, corresponding to a protective effect on AMD. Next, we calculated the PAF for each single variant. The *ARMS2* variant rs3750846 was associated with a large PAF (0.3) for late AMD, whereas variants in *CFH* exhibited both the largest PAF (0.33 for rs570618) and the largest inverse PAF (−0.37 for rs10922109; Fig 1B). A similar pattern with smaller PAFs was observed for intermediate AMD. Only variant rs11080055 in *TMEM97*/*VTV* showed a higher PAF for intermediate (0.063) than for late (0.024) AMD. Only 4 late AMD patients (0.2% [4/1777]) did not carry any of the 5 major risk SNPs, compared with 33 control participants (1% [33/3167]).

Genetic Risk Score for Age-Related Macular Degeneration

We subsequently combined all genetic variants in a GRS and assessed its distribution. In the population-based cohort studies (*n* = 13 194), the score ranged from −3.50 to 4.63 (mean, 0.40; SD, 1.24) and showed a normal distribution (Fig 2A). With respect to the distribution per phenotype, the GRS in control participants ranged from −3.03 to 3.94 (mean, 0.26; SD, 1.16), that in intermediate AMD patients ranged from −3.11 to 4.71 (mean, 0.83; SD, 1.33), and that in late AMD patients ranged from −3.00 to 6.23 (mean, 1.64; SD, 1.32; Fig 2B). Although the lowest GRS value was similar for all phenotypes, the entire distribution showed a significant increase with increasing AMD severity (*P* < 0.0001, Jonckheere-Terpstra test for ordered alternatives). When stratifying late AMD into GA and CNV, slightly higher scores were noted for CNV (Fig 2C) that for GA ranged from −2.72 to 4.87 (mean, 1.46; SD, 1.41) and that for CNV ranged from −3.00 to 6.23 (mean, 1.67; SD, 1.30; *P* = 0.01, independent-sample *t* test). We estimated the discriminative accuracy of a score based on the 49 AMD-associated genetic variants (Figs S3 and S4, available at www.aaojournal.org) for identification of late AMD; the area under the receiver operating characteristic curve was 0.838. We identified a minimal set of variants by using the leave-one-out principle and found an almost identical area under the receiver operating characteristic curve (0.837) when including 27 AMD-associated variants (Genetic Risk Score for Age-Related Macular Degeneration and the Supplemental Appendix, available at www.aaojournal.org).

Genetic Risk Scores per Pathway

Next, we constructed pathway-specific GRSs for the complement, lipids, ECM, *ARMS2*, and other pathways. The complement pathway score ranged from −3.15 to 3.64 in the population-based studies, and 55% of participants scored more than 0 for this pathway. The *ARMS2* score ranged from 0 to 2.15 because only 1 risk variant determines this score. The lipid pathway showed a GRS ranging from −1.44 to 0.49, and the ECM pathway showed a GRS ranging from −0.92 to 1.46, and 36% and 33%, respectively, showed a score of more than 0. The pathway other ranged from −1.06 to 1.45, and 61% showed a positive score.

The distribution of all pathway GRSs in our total study population showed a positive shift with increasing AMD severity (*P* < 0.0001, Jonckheere-Terpstra test for ordered alternatives; Table S1, available at www.aaojournal.org; Fig 5), but the complement and *ARMS2* GRS demonstrated the largest increase for late AMD, especially when combined (shift of mean GRS from 0.39 to 1.59).

Frequency of Positive Genetic Risk Score

We studied the proportion of individuals with a positive (>0) GRS for each of the pathways, because this indicates more genetic risk than protection from that particular pathway. Positive GRSs for all pathways were most




Figure 2. A, Bar graph showing the distribution of the total age-related macular degeneration (AMD) genetic risk score (GRS) in the European population. B, Bar graphs showing distributions of the total AMD GRS: (top panel) control participants (age, ≥ 75 years), (middle panel) intermediate AMD, and (bottom panel) late AMD. C, Bar graphs showing the distributions of the total AMD GRS: (left panel; light blue) frequency of geographic atrophy (GA) for each total AMD GRS and (right panel; green) frequency of choroidal neovascularization (CNV) for each total AMD GRS, both on a log scale.




Figure 5. Bar graphs showing the distributions of the genetic risk scores for the (A) complement, (B) lipids, (C) extracellular matrix, (D) ARMS2, and (E) other pathways and (F) the complement with ARMS2 combined pathways in control participants and late age-related macular degeneration (AMD) patients.

complement and ARMS2 pathways, only 5 late AMD patients (0.3%) showed no risk allele in this pathway.

Next, we calculated the distribution of pathways with a GRS of more than 0 (Fig 8). Most participants showed 2 to 4 pathways with a GRS of more than 0 (85%). A small proportion (7%) of individuals showed a GRS in only 1 pathway of more than 0, and an even smaller proportion (1% [n = 23]) of individuals showed a GRS of 0 or less for all pathways.

Combining Genetics with Lifestyle

Data on lifestyle factors were available for a subset of the study population (n = 3525). In these participants, we

investigated the AMD lifestyle factors of smoking and dietary intake of vegetables, fruit, and fish. Patients more often were current smokers (OR, 1.39) and consumed fewer vegetables (OR, 0.40), less fruit (OR, 0.35), and less fish (OR, 0.17; $P < 0.0001$ for all; Table S3, available at www.aaojournal.org). We composed a lifestyle score based on these variables and stratified the score into tertiles: favorable, intermediate, and unfavorable lifestyle. For each GRS category (also tertiles), we observed that the more unfavorable the lifestyle, the higher the risk of late AMD. Lifestyle increased the risk 2 to 2.3 times depending on the genetic risk. In the highest genetic risk group, the OR increased from 14.9 to 35.0 in individuals with an unfavorable lifestyle (Fig 9).




Figure 6. Bar graph showing the percentage of individuals with a positive genetic risk score for each of the pathways. Dark blue, control participants 75 years of age or older; light blue, intermediate age-related macular degeneration (AMD) patients; green, late AMD patients. The asterisk (*) indicates statistical differences in a Pearson chi-square test (2-sided) with $P < 0.0001$; $P = 0.0028$ with Bonferroni correction for multiple testing. ECM = extracellular matrix.

Discussion

This study provides a comprehensive interpretation of AMD genetic risk in the European population. The risk allele most discriminative between late AMD patients and control participants was located in *ARMS2*, closely followed by a risk-increasing and a protective allele in *CFH*. We observed a normal distribution of AMD-associated GRS, with variants increasing disease risk, but also a significant number offering protection against

AMD. Patients with late AMD showed higher GRSs than control participants. Mathematically, we showed that the genetic contribution of the complement pathway and *ARMS2* to late AMD was at least 90%. However, most patients carried genetic risk in multiple pathways, signifying the complex cause of AMD. All persons benefitted from a healthy lifestyle, but those with a high GRS showed the strongest risk reduction. This highlights the possibilities of counteracting predicted disease outcomes with lifestyle choices.




Figure 8. Bar graph showing the number of late age-related macular degeneration patients with positive pathway scores. Numbers inside the bars indicate the frequency.

Subgroup	Cases/Controls	Odds Ratio	CI 95%	P-value
Low genetic risk				
Favorable lifestyle	27/292	1 reference		
Intermediate lifestyle	46/250	1.99	1.30-3.30	0.007
Unfavorable lifestyle	37/198	2.02	1.19-3.43	0.009
Intermediate genetic risk				
Favorable lifestyle	51/207	2.67	1.62-4.39	<0.0001
Intermediate lifestyle	84/167	5.44	3.39-8.73	<0.0001
Unfavorable lifestyle	95/170	6.04	3.79-9.65	<0.0001
High genetic risk				
Favorable lifestyle	124/90	14.90	9.23-24.05	<0.0001
Intermediate lifestyle	198/84	25.94	15.94-40.77	<0.0001
Unfavorable lifestyle	230/71	35.03	21.77-56.37	<0.0001




Figure 9. Table and graph showing the odds ratio of risk for late age-related macular degeneration (AMD) stratified by genetic risk score (GRS) and lifestyle risk. CI = confidence interval.

Our results need to be seen in light of the strengths and limitations of this study. An important strength was the very large number of Europeans included in this study. From the E3 Consortium, we included 9 studies with genetic data, that is, population studies from The Netherlands, France, and Portugal, as well as case-control studies from The Netherlands and Germany. Data were harmonized and entered into a single database, which allowed us to perform in-depth analyses on combinations of phenotype, genotype, and lifestyle factors in the pooled dataset. Grouping genes into pathways and calculating pathway-specific genetic susceptibility enabled us to study molecular drivers and personalized risks. A limitation of our study was the incompleteness of data on several determinants in some studies. We focused on 49 genetic variants that were associated individually with AMD,⁵ of which only few were rare. Hence, we cannot elaborate on risks provided by most of the currently known rare variants. The studies providing the greater part of patients were case-control studies without follow-up data, and therefore we were restricted to cross-sectional analyses.

A positive GRS indicated more causative genetic risk than protection by genetic variants. Because this was present in 63% of the population (2546/4044), we conclude that genetic susceptibility to AMD is highly prevalent. Among patients with late AMD, the proportion of a positive GRS rose to 89% (1581/1777). We investigated this in greater detail and found that the 5 major risk alleles were absent in only 66 persons (1%), indicating that 99% of the study population carried at least 1 major risk allele. By contrast, on average, 2.5 major risk alleles were present among late AMD patients and were absent in only 0.2% (4/1777). A set of 27 risk variants was enough to reach discriminative accuracy 0.84 for late AMD versus no AMD. Adding more variants did not improve this further, and the area under the receiver operating characteristic curve was in line with previous studies.^{13,14} It should be emphasized that such high discrimination based solely on genetic variants is exceptional for a complex disorder, although this is still challenging at mean GRS levels.

Considering individual pathways, 19 of 52 common AMD risk variants are in the complement pathway.⁵ Previous studies have reported already that common variants in the complement pathway explain 57% of the

heritable risk of AMD,¹⁵ and our study underscores the high attribution of this pathway to the overall GRS. Comparing the risk of the most important *CFH* SNP (rs570618 in high linkage disequilibrium (LD) 0.991 with rs1061170, Y402H) with an Asian population, we and others observed only a slightly higher OR of late AMD in Europeans (2.47 vs. 2.09)¹⁶ but very different allele frequencies (minor allele frequency, 0.34 vs. 0.049).¹⁷ With respect to function, the complement pathway is part of the innate immune system, and numerous studies have shown that imbalance of this cascade at the protein level is important for AMD pathogenesis. Genetically, this system harbors strong causative as well as highly protective risk alleles (Fig 1), which mathematically can add up to a GRS of 0. Whether this also reflects a neutral risk at the tissue level is unclear, because persons with late AMD and a negative GRS for the complement pathway still carried risk-increasing alleles in this pathway. Nevertheless, the risk-reducing effect of these protective alleles are of high biological interest, and investigation into the functional consequences may provide leads for future therapy.

The rs3750846 (or its proxy, rs10490924, A69S) variant in the *ARMS2* locus carried the highest risk of late AMD and the second highest attribution to overall AMD occurrence in our study (Fig 1). In East Asia, this allele is twice as common (minor allele frequency, 0.40 in East Asians vs. 0.19 in Europeans), but the risk of late AMD for carriers seems comparable (OR, 2.94 in India vs. OR, 3.06 in Europe).^{18,19} The function of *ARMS2* is the subject of ongoing research. Recently, Micklisch et al¹¹ showed in vitro that *ARMS2* functions as a surface complement regulator by binding to the cell membrane of apoptotic and necrotic cells and that it subsequently binds properdin and activates complement. This provides evidence that *ARMS2* can be an initiator of complement. We considered 2 different scenarios for the pathway of *ARMS2*: a function in the complement pathway and an independent function. When regarded as a complement gene, the vast majority (90%) of late AMD patients showed an increased genetic risk in this pathway, making complement the main driver of late AMD. As a stand-alone function, *ARMS2* also provided a significant contribution because it was present in two thirds of late AMD patients.

Variants in the lipid and ECM pathways showed smaller effects and attribution to overall late AMD. Variants in genes with other functions (the other pathway) also showed smaller effects, but the 16 variants combined were rather frequent and predisposed considerably to late AMD.

We further investigated the impact of the most important lifestyle factors, smoking and diet, in relationship to genetic risk. As expected, persons with AMD showed a lower intake of vegetables, fish, and fruit and higher rates of smoking (Table S3).^{20–26} Together, a more unfavorable lifestyle almost doubled the risk of late AMD. This occurred in all genetic risk strata, but the OR increase was most prominent in those at high genetic risk. These findings confirm previous reports from the Rotterdam Study^{27,28} and Age-Related Eye Disease Study, which demonstrated interaction between single nutrients and *CFH* and *ARMS2* and a protective role of diet in those with a high GRS.²⁹ The current study analyzed a more comprehensive set of risk variants and found that a healthy diet and not smoking also were beneficial in persons with low genetic risk. Oxidative stress is the most recognized molecular effect of smoking in the pathogenesis of AMD,³⁰ and antioxidants are the most important contribution to a healthy diet. Oxidative stress with abundant reactive oxygen species, peroxidation of lipids, proteins, RNA, and DNA in the retina can lead to cytotoxic effects and inflammation, enhancing the development of

AMD.³¹ Unfortunately, a healthy diet consisting of sufficient fruits, vegetables, and fatty fish is consumed by only a minority of the elderly,²⁸ and smoking is still twice as high among those with late AMD (Table S3). This asks for more rigorous measures for prevention, and training of doctors in behavioral change techniques may be part of this.

In conclusion, this large European consortium showed that genetic risk of AMD is highly prevalent in the population at large and that risk variants in the complement pathway are by far the lead drivers of late AMD. Nevertheless, late AMD is mostly a result of multiple genetic pathways and lifestyle choices. The frequency and risk estimates provided by this study can lay the foundation for future intervention studies that are tailored to pathways.

Acknowledgments

The authors thank the study participants; the staff from the Rotterdam Study; the participating general practitioners and pharmacists; Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for help in creating the GWAS database; and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. We thank Benjamin Grenier-Boley, Céline Bellenguez, Jean-Charles Lambert, and Philippe Amouyel for the creation and analysis of the imputed data.

Footnotes and Disclosures

Originally received: March 25, 2020.

Final revision: November 17, 2020.

Accepted: November 23, 2020.

Available online: November 28, 2020. Manuscript no. D-20-00606.

¹ Department of Ophthalmology, Erasmus University Medical Center, Rotterdam, The Netherlands.

² Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.

³ Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

⁴ Coimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.

⁵ Department of Ophthalmology, Coimbra Hospital and University Center, Coimbra, Portugal.

⁶ Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal.

⁷ Team LEHA, Bordeaux Population Health Research Center, Inserm, Université de Bordeaux, Bordeaux, France.

⁸ Department of Ophthalmology, University Hospital Cologne, Cologne, Germany.

⁹ Hoffmann-La Roche AG, Basel, Switzerland.

¹⁰ Randall Division of Cellular and Molecular Biophysics, King's College London, London, United Kingdom.

¹¹ Department of Mathematics, King's College London, London, United Kingdom.

¹² Department of Ophthalmology, University Hospital, Eye and Nutrition Research Group, INRAe, Dijon, France.

¹³ Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.

¹⁴ Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.

¹⁵ Institute of Molecular and Clinical Ophthalmology, Basel, Switzerland.

*A complete listing of the members of the [EYE-RISK Consortium](http://www.aaojournal.org) is available at www.aaojournal.org

Disclosure(s):

All authors have completed and submitted the ICMJE disclosures form.

The author(s) have made the following disclosure(s): R.S.: Consultant – Alimera, Allergan, Alcon, Bayer, Novartis, THEA, Novo Nordisk

B.M.J.M.: Consultant – Thea Pharma, Bausch & Lomb; Financial support Thea Pharma, Synadiet

A.C.-G.: Financial support – Thea Pharma

S.F.: Employee – Roche

C.C.-G.: Financial support – Allergan, Bayer, Roche, Bausch & Lomb, Novartis, Théa, Horus; Nonfinancial support – Bayer

M.U.: Consultant – Roche

C.D.: Consultant – Allergan, Bausch & Lomb, Laboratoires Théa, Novartis, Roche

A.I.dH: Consultant – Ionis Pharmaceuticals, Gyroscope Therapeutics, Gemini Therapeutics, Roche

C.C.W.K.: Consultant – Bayer, Laboratoires Théa, Novartis.

Supported by the European Union (Horizon 2020 grant no.: 634479 [EYE-RISK]). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, The Netherlands; The biobank CORRBI of both Department of Ophthalmology and the Rotterdam Eye Hospital is financed through the CORR (Combined Ophthalmic Research Rotterdam)

Foundation; The ophthalmic research within the Rotterdam Study was supported by Uitzicht grant number: 2015-36, Oogfonds, MaculaFonds, LSBS, Novartis Fonds. The sponsors and funding organization had no role in the design or conduct of this research; the Netherlands Organization for the Health Research and Development; the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. The Alienor-3C study received financial support from Laboratoires Théa (Clermont-Ferrand, France), Fondation Voir et Entendre (Paris, France), and Caisse Nationale de Solidarité pour l'Autonomie (Paris, France). Laboratoires Théa participated in the design of the study, but no sponsor participated in the collection, management, statistical analysis and interpretation of the data, nor in the preparation, review or approval of the present manuscript. The genome-wide association study genotype data for the Alienor-3C study are managed by the RID-AGE (Risk factors and molecular determinants of aging-related diseases) group of University of Lille, Institut Pasteur de Lille, and INSERM U1167 (Lille, France). MONRACHET funding was provided by an Inter-regional grant (Programme Hospitalier de Recherche Clinique [PHRC]) and the Regional Council of Burgundy. This study was also funded by INRA, CNRS, Université de Bourgogne, Regional Council of Burgundy France (PARI Agrale 1), FEDER (European Funding for Regional Economic Development) and French Government grant managed by the French National Research Agency (ANR) as part of the "Investissements d'Avenir" program (reference ANR-11-LABX-0021-01-LipS-TIC Labex). The funding organizations had no role in the design or conduct of this research. The Coimbra Eye Study is an Investigator-Initiated Study sponsored by AIBILI that was financially supported by Novartis Pharma AG. The funding organization played no role in the design or conduct of this research. Supported in part by grants from Deutsche Forschungsgemeinschaft HE 2293/5-1, 5-2, 5-3; the Intramural IMF fund of the University of Muenster; the Pro Retina Foundation; and the Jackstaedt Foundation. EUGENDA was funded by grants from the Oogfonds, MaculaFonds, Landelijke Stichting voor Blinden en Slechtzienden, Stichting Blindenhulp, Stichting A.F. Deutman Oogheelkunde Researchfonds, the Netherlands Organization for Scientific Research (Vidi Innovational Research Award 016.096.309), and the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) (ERC Grant Agreement no. 310644 MACULA). This research was supported by the Dutch Organization for Scientific Research (016.Vici.170.024 to AldH). The ophthalmic research within the Rotterdam Study was supported by Uitzicht grant number: 2015-36, Oogfonds, MaculaFonds, LSBS, Novartis Fonds. The sponsors and funding organization had no role in the design or conduct of this research.

The generation and management of GWAS genotype data for the Rotterdam Study (I, II, and III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nos.: 175.010.2005.011 and 911-03-012); the Genetic Laboratory of the

Department of Internal Medicine, Erasmus MC; the Research Institute for Diseases in the Elderly (grant no.: 014-93-015 [RIDE2]); the Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research and Netherlands Consortium for Healthy Aging (grant no.: 050-060-810).

HUMAN SUBJECTS: Human subjects were included in this study. The recruitment and research protocols were reviewed and approved by the local institutional review boards: the Alienor-3C study was approved by the Ethical Committee of Bordeaux (Comité de Protection des Personnes Sud-Ouest et Outre-Mer III); the Coimbra eye study was approved by the Association for Innovation and Biomedical Research on Light and Image (AIBILI) Ethics Committee; the CORRBI study was approved by the medical ethics review committee of the Erasmus Medical Center, Rotterdam, the Netherlands; the EUGENDA study was approved by the ethics committees in Cologne and Nijmegen; the MARS study was approved by the Institutional Review Board of the University of Muenster; the Montrachet-3C study was approved by the Ethical Committee of the University Hospital of Kremlin-Bicêtre; the Rotterdam Studies I, II, and III were approved by the Medical Ethics Committee of the Erasmus MC (registration number: MEC 02.1015); and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). Informed consent was obtained from all study participants in compliance with the Declaration of Helsinki.

No animal subjects were included in this study.

Author Contributions:

Conception and design: Colijn, Meester, Verzijden, Delcourt, den Hollander, Klaver

Analysis and interpretation: Colijn, Verzijden, Coolen, Delcourt, den Hollander, Klaver

Data collection: Colijn, Verzijden, de Breuk, Silva, Merle, Cougnard-Grégoire, Hoyng, Fauser, Coolen, Creuzot-Garcher, Hense, Ueffing, Delcourt, den Hollander, Klaver

Obtained funding: Ueffing, Klaver, Delcourt, den Hollander, Hoyng

Overall responsibility: Colijn, Meester, Ueffing, Klaver

Abbreviations and Acronyms:

AMD = age-related macular degeneration; **CNV** = choroidal neovascularization; **ECM** = extracellular matrix; **E3** = European Eye Epidemiology; **GA** = geographic atrophy; **GRS** = genetic risk score; **GWAS** = genome-wide association study; **LD** = linkage disequilibrium; **MAF** = minor allele frequency; **OR** = odds ratio; **PAF** = population-attributable fraction; **RPE** = retinal pigment epithelium; **RS** = Rotterdam Study; **SD** = standard deviation; **SNP** = single nucleotide polymorphism; **WARGMS** = Wisconsin Age-Related Maculopathy Grading System.

Keywords:

Age-related macular degeneration, Europe, Genetics, Pathways, Population.

Correspondence:

Caroline C.W. Klaver, PhD, Department of Ophthalmology, Erasmus Medical Centre, P. O. Box 2040, NL-3000 CA Rotterdam, The Netherlands. E-mail: c.c.w.klaver@erasmusmc.nl.

References

- Colijn JM, Buitendijk GHS, Prokofyeva E, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. *Ophthalmology*. 2017;124(12):1753–1763.
- Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):e106–e116.
- McLeod DS, Grebe R, Bhutto I, et al. Relationship between RPE and choriocapillaris in age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2009;50(10):4982–4991.
- Keenan TD, Vitale S, Agron E, et al. Visual acuity outcomes after anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Age-Related Eye Disease Study 2 report number 19. *Ophthalmol Retina*. 2019;4:3–12.
- Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nat Genet*. 2016;48(2):134–143.
- Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: a review of

- rare genetic variants and implications for personalized treatment. *Mol Immunol*. 2017;84:65–76.
7. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. *Ophthalmology*. 2014;121(3):693–701.
 8. Wu J, Sun X. Complement system and age-related macular degeneration: drugs and challenges. *Drug Des Devel Ther*. 2019;13:2413–2425.
 9. Delcourt C, Korobelnik JF, Buitendijk GH, et al. Ophthalmic epidemiology in Europe: the “European Eye Epidemiology” (E3) consortium. *Eur J Epidemiol*. 2016;31(2):197–210.
 10. de Breuk AI, Acar IE, Kersten E, et al; EYE-RISK Consortium. Development of a genotype assay for age-related macular degeneration: the EYE-RISK Consortium. *Ophthalmology*. 2020 Jul 25:S0161-6420(20)30725-9. doi: 10.1016/j.ophtha.2020.07.037. Epub ahead of print. PMID: 32717343.
 11. Micklisch S, Lin Y, Jacob S, et al. Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. *J Neuroinflammation*. 2017;14(1):4.
 12. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. *Am J Epidemiol*. 1974;99(5):325–332.
 13. Jakobsdottir J, Gorin MB, Conley YP, et al. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. *PLoS Genet*. 2009;5(2):e1000337.
 14. Grassmann F, Fritsche LG, Keilhauer CN, et al. Modelling the genetic risk in age-related macular degeneration. *PLoS One*. 2012;7(5):e37979.
 15. Fritsche LG, Fariss RN, Stambolian D, et al. Age-related macular degeneration: genetics and biology coming together. *Annu Rev Genomics Hum Genet*. 2014;15:151–171.
 16. Maugeri A, Barchitta M, Agodi A. The association between complement factor H rs1061170 polymorphism and age-related macular degeneration: a comprehensive meta-analysis stratified by stage of disease and ethnicity. *Acta Ophthalmol*. 2019;97(1):e8–e21.
 17. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD: National Center for Biotechnology Information, National Library of Medicine, 2019; v. 2019. Available at: <http://www.ncbi.nlm.nih.gov/SNP>. Accessed 30-11-2019.
 18. Jabbarpoor Bonyadi MH, Yaseri M, Nikkiah H, et al. Comparison of ARMS2/LOC387715 A69S and CFH Y402H risk effect in wet-type age-related macular degeneration: a meta-analysis. *Int Ophthalmol*. 2019;39(4):949–956.
 19. Rajendran A, Dhoble P, Sundaresan P, et al. Genetic risk factors for late age-related macular degeneration in India. *Br J Ophthalmol*. 2018;102(9):1213–1217.
 20. Hogg RE, Woodside JV, McGrath A, et al. Mediterranean diet score and its association with age-related macular degeneration: the European Eye Study. *Ophthalmology*. 2017;124(1):82–89.
 21. Merle BMJ, Colijn JM, Cougnard-Gregoire A, et al. Mediterranean diet and incidence of advanced age-related macular degeneration: the EYE-RISK Consortium. *Ophthalmology*. 2019;126(3):381–390.
 22. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. *JAMA*. 1996;276(14):1141–1146.
 23. Myers CE, Klein BE, Gangnon R, et al. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. *Ophthalmology*. 2014;121(10):1949–1955.
 24. Merle B, Delyfer MN, Korobelnik JF, et al. Dietary omega-3 fatty acids and the risk for age-related maculopathy: the Alienor Study. *Invest Ophthalmol Vis Sci*. 2011;52(8):6004–6011.
 25. Seddon JM, George S, Rosner B. Cigarette smoking, fish consumption, omega-3 fatty acid intake, and associations with age-related macular degeneration: the US Twin Study of Age-Related Macular Degeneration. *Arch Ophthalmol*. 2006;124(7):995–1001.
 26. SanGiovanni JP, Chew EY, Agron E, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. *Arch Ophthalmol*. 2008;126(9):1274–1279.
 27. Ho L, van Leeuwen R, Witteman JC, et al. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam Study. *Arch Ophthalmol*. 2011;129(6):758–766.
 28. de Koning-Backus APM, Buitendijk GHS, Kiefte-de Jong JC, et al. Intake of vegetables, fruit, and fish is beneficial for age-related macular degeneration. *Am J Ophthalmol*. 2019;198:70–79.
 29. Age-Related Eye Disease Study Research Group, SanGiovanni JP, Chew EY, et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS report no. 22. *Arch Ophthalmol*. 2007;125(9):1225–1232.
 30. Schmidt S, Hauser MA, Scott WK, et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. *Am J Hum Genet*. 2006;78(5):852–864.
 31. Schutt F, Bergmann M, Holz FG, Kopitz J. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. *Invest Ophthalmol Vis Sci*. 2003;44(8):3663–3668.